The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer.

Nirmatrelvir-ritonavir may lower risk of intubation or in-hospital mortality in patients with severe COVID-19.

The Covid-19 mRNA-based vaccines that saved 2.5 million lives globally during the pandemic could help spark the immune system to fight cancer. This is the surprising takeaway of a new study that we ...

The virus has a fatality rate ranging from 40 per cent to 75 per cent, according to health experts. There is currently no ...

Researchers continue looking at existing medicine for help in the fight against the novel coronavirus, because those drugs already exist and could quickly make a big difference. The latest lead for ...

Millions of COVID-19-associated illnesses and outpatient visits as well as thousands of hospitalizations and deaths continued to occur annually in the United States from late 2022 through 2024, ...

Nipah Virus Outbreak: Chinese researchers claim COVID-19 drug can fight the deadly infection - All you need to know ...

Investing.com -- Traws Pharma Inc (NASDAQ:TRAW) stock surged 14.5% Monday after the clinical-stage biopharmaceutical company announced the completion of enrollment in its Phase 2 study of ratutrelvir, ...

Moderna COVID-19 vaccines were associated with a threefold increased risk of chronic urticaria and nearly fourfold increased risk of other types of urticaria compared to expected rates.